ArticleContemporary oncology (Poznan, Poland)2025
Treatment of oligometastatic non-small cell lung cancer with radiotherapy - single-centre experience.
Article in Contemporary oncology (Poznan, Poland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Prognostic Role ofCancers · 2026Article
- Beyond the Scan: Adapting Multimodal Lung Cancer Screening for Central and Eastern Europe-Overcoming Systemic Barriers and Epidemiological Confounders.Medical sciences (Basel, Switzerland) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Lung cancer is one of the most common malignancies in the world. Many attempts have been made to increase survival of this devastating disease, including the addition of local therapies in oligometastatic non-small cell lung cancer (OMD NSCLC). Oligometastatic disease is an intermediate state between a local and widely disseminated disease. The aim of the study was to assess the efficacy of stereotactic radiation therapy (SRT) in treatment of OMD NSCLC and to evaluate prognostic factors for survival. Material and methods: Medical records of 127 consecutive patients with OMD NSCLC who underwent SRT in University Clinical Centre in Gdańsk, Poland between 2016 and 2022 were obtained and clinical data were analysed for toxicity and efficacy. Results: There were 64.6% of patients with adenocarcinoma, 25.2% with squamous-cell carcinoma and 10.2% with other histological subtypes. Mean age was 66.9 years. Treatment was well tolerated in the majority of patients. Median progression-free survival (PFS) for synchronous OMD (sOMD) and metachronous OMD (mOMD) was 11.1 months and 14.4 months, respectively ( Conclusions: Radical treatment in OMD NSCLC should be judicious and reserved for selected patients. Stereotactic radiation therapy is an important tool in the management of OMD NSCLC.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.